Akumin — Q4 2021 Earnings Presentation
20 slides from Akumin's earnings presentation, March 2022
Slide 1: Q4 2021 Results
Akumin Inc. Q4 2021 Results March 2022 Riadh Zine, Chairman & Co-CEO Rhonda Longmore-Grund, President & Co-CEO Bill Larkin, Chief Financial Officer
Slide 2: Disclaimer and Disclosure
Disclaimer and Disclosure Forward-Looking Statements This presentation may contain forward-looking information or forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and/or applicable Canadian securities legislation (collectively, “forward-looki
Slide 3: Akumin At a Glance
Akumin At a Glance • #2 overall radiology services provider: ~2 million procedures/year in 46 states • #1 provider of PET/CT services • #2 provider of MRI services • #2 fixed site clinic locations • #1 mobile radiology provider • #2 provider of radiation therapy services to U.S. hospitals treating m
Slide 4: Comprehensive Outpatient Solutions Provider to Hospitals and Health Systems
Comprehensive Outpatient Solutions Provider to Hospitals and Health Systems, Leveraging Growing Fixed Site Footprint On-Campus Outpatient Mobile Outpatient Networks Fixed Sites Fixed Sites • Shared platform, part-time, • Within or adjacent to hospital • Convenient location • Market or regional leade
Slide 5: Diverse Service Lines and Modalities
Diverse Service Lines and Modalities • Diversification of revenue between Service Lines (% of Revenue) 1 Radiology and Oncology Radiology Procedure Mix divisions (% of Revenue) • Akumin provides a full suite of radiology and oncology services with a focus on high-growth and high-value modalities 1 P
Slide 6: Diverse Payor Mix for Outpatient Services
Diverse Payor Mix for Outpatient Services 2021 Pro Forma ~95% of the company’s overall Payor Mix1 revenue is derived from (% of Revenue) outpatient procedures • 50% of revenue is received 1 1 via third party and government payers, for reimbursed at outpatient rates • 50% of revenue is received via h
Slide 7: 2021 Achievements at a Glance
2021 Achievements at a Glance • Completed the acquisition of Alliance HealthCare Services on September 1st, 2021 – creating the most comprehensive outpatient solutions provider to hospitals and health systems, leveraging our growing fixed site platform. • Launched integration efforts which will yiel
Slide 8: Q4 2021 Performance Highlights
Q4 2021 Performance Highlights • Same Store Volumes on a pro forma basis across the platform continued to trend positively: • MRI: +6.2% • PET/CT: +4.2% • Total Radiology Procedures: +3.0% • Total Oncology Patient Starts: +4.5% • New hospital contract sales coupled with strong retention generated ne
Slide 9: The Omicron Surge Impact
The Omicron Surge Impact • Omicron surge of COVID-19 began late in the fourth quarter, impacting our typical patient volumes as well staffing at both our fixed and mobile sites of service. • In Q4, we had 757 team members who missed one or more days of work due to COVID-19-related illness, isolation
Slide 10: Radiology Volume Trends - Pro Forma
Radiology Volume Trends - Pro Forma • Same Store MRI Volume Growth: +6.2% in Q4 2021; +14.4% in 2021 • Same Store PET/CT Volume Growth: +4.2% in Q4 2021; +5.9% in 2021 • Same Store Total Procedures Volume Growth: +3.0% in Q4 2021; +12.8% in 2021 Same Store Volume Growth Total Volumes MRI PET/CT Tota
Slide 11: Oncology Volume Trends – Pro Forma
Oncology Volume Trends – Pro Forma • Same Store Patient Start Volume Growth: +4.5% in Q4 2021, +3.8% YTD 2021 • Patient Start Volume has returned to pre-pandemic (2019) levels Same Store Patient Start Volume Growth1 Total - Patient Starts Volume1 Total - Revenue Per Patient Start1 1 Total Patient St
Slide 12: Financial Performance Trend Statutory (As Reported) and Pro Forma
Financial Performance Trend Statutory (As Reported) and Pro Forma Revenue1 Adjusted EBITDA2 ($M) ($M) Maintenance Capex3 Growth Capex3 ($M) ($M) 1 Pro forma Normalized Revenue excludes Interventional and AO of AZ Revenue of $73.3M, $57.9M, $18.7M, for FY19, 20 and 21 respectively due to sale of segm
Slide 13: Segment Financial Performance Statutory & Pro Forma
Segment Financial Performance Statutory & Pro Forma Q4 2021 Statutory 2021 Statutory ($ in M) RAD ONC Corp Total ($ in M) RAD ONC Corp Total Revenue $ 145.9 $ 33.5 $ - $ 179.4 Revenue $ 374.4 $ 46.7 $ - $ 421.1 % vs PY - Fav(Unfav) 118.2% 168.3% % vs PY - Fav(Unfav) 52.4% 71.4% Adjusted AEBITDA $ 23
Slide 14: 2022 Guidance
2022 Guidance • Full year of combined enterprise • Positive same store volume across the platform • Strong new customer acquisition as well as retention • Revenue range $760M-$780M • 2021 Revenue of $421M. Includes four months of Alliance acquisition vs twelve months in 2022 guidance. • Adjusted EBI
Slide 15: 2022 Guidance Assumptions and Risk Factors
2022 Guidance Assumptions and Risk Factors 2021 vs 2022 PF Revenue PF Adj EBITDA 2021 Normalized 1 $ 727 $ 146 2022 Midpoint $ 778 $ 161 2022 Plan Incr/(Decr) vs 2021 $ 50 $ 14 • $50M increase in Revenue • Growth related to same store revenue growth and contribution from new business development ini
Slide 16: Integration / Synergy Assumptions
Integration / Synergy Assumptions Integration Cost Synergy Potential The $23 million in estimated cost synergies are related to Phase 1 and equipment maintenance overhaul in Phase 2. More upside in cost savings expected to arise from a number of initiatives as outlined in both Phase 2 and Phase 3. 0
Slide 17: Free Cash Flow Generation
Free Cash Flow Generation The company expects to generate free cash flows of ~$55M as per the following assumptions: • Mid range of the 2022 2022 2022 guidance FY2021 Midpoint Run Rate Adjusted EBITDA $ 66.9 $ 160.6 186.8 (1) • Full deployment of 2022 Growth CAPEX of $59M and Less: Maintenance Capex
Slide 18: Capital Structure – A Solid Foundation for Growth
Capital Structure – A Solid Foundation for Growth Total Secured Debt $ 908.8 Akumin’s capital structure is comprised Less: Cash 48.4 of a diverse set of capital providers Net Secured Debt $ 860.4 including traditional banks, bondholders and Stonepeak as debt and equity 1 Adj. EBITDA $ 160.6 stakehol
Slide 19: Thank you!
Thank you! Riadh Zine, Chairman & Co-CEO Rhonda Longmore-Grund, President & Co-CEO Bill Larkin, Chief Financial Officer
Slide 20: Appendix 1: Reconciliation of EBITDA and Adjusted EBITDA to Net Loss
Appendix 1: Reconciliation of EBITDA and Adjusted EBITDA to Net Loss Year Ended December 31 (in thousands) 2021 2020 Net loss $(34,814) $ (34,156) Interest expense 62,575 32,781 Income tax expense (benefit) (30,391) 562 Depreciation and amortization 44,895 17,060 EBITDA 42,265 16,247 Adjustments: St